Company Filing History:
Years Active: 2003
Title: Inventor Spotlight: Klaus Schughart
Introduction
Klaus Schughart is a notable inventor based in Kenzingen, Germany, recognized for his contributions to the field of gene therapy. With a strong background in biomedicine, he has developed innovative formulations that enhance the delivery of therapeutically active substances to target cells.
Latest Patents
Klaus Schughart holds a patent titled "Compositions for the delivery of polynucleotides to cells." This invention pertains to a specialized composition designed for transferring at least one therapeutically active substance into the interior of a target cell. The composition comprises a mixture of a therapeutically active substance, preferably a polynucleotide, and at least one polar compound selected from a specific group of aprotic polar compounds. Notably, the polar compound identified in his patent is DPSO, which significantly improves the efficiency of polynucleotide transfection into cells. The applications of this invention extend to diagnostic, therapeutic, prophylactic, or vaccinal medications aimed at treating both human and animal bodies through gene therapy.
Career Highlights
Klaus Schughart is affiliated with Transgene S.A., a company focused on developing immunotherapies for cancer and infectious diseases. His role involves research and development, where he applies his expertise in the innovative transformations of biotherapeutics. With one patent under his name, he has successfully contributed to advancements in therapeutic delivery systems.
Collaborations
Throughout his career, Klaus has collaborated with esteemed colleagues, including Rainer Bischoff and Hanno V. Kolbe. These partnerships have been instrumental in fostering innovation within the field, enabling the collective exploration of novel therapeutic approaches and methodologies in gene therapy.
Conclusion
Klaus Schughart exemplifies the spirit of innovation in the realm of biomedical technology. His patented work on compositions for delivering polynucleotides represents a significant advancement in gene therapy, offering new possibilities for treatment applications. His collaborations and contributions to Transgene S.A. further our understanding and capabilities in therapeutic developments that hold the potential to transform patient care.